News Aerovate Therapeutics, Inc.

Equities

AVTE

US0080641071

Delayed Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
20.57 ^USD	-6.12%		+3.73%	-9.10%

May. 13	Aerovate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 12	Aerovate Therapeutics Insider Sold Shares Worth $334,478, According to a Recent SEC Filing	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aerovate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights	May. 13	AQ
Aerovate Therapeutics : May 2024 Corporate Presentation	May. 02	PU
Aerovate Therapeutics Insider Sold Shares Worth $334,478, According to a Recent SEC Filing	Apr. 12	MT
Aerovate Therapeutics Insider Sold Shares Worth $300,033, According to a Recent SEC Filing	Apr. 04	MT
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference	Mar. 27	AQ
Aerovate Therapeutics Q4 Loss Widens	Mar. 25	MT
Aerovate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Aerovate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 25	CI
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights	Mar. 25	AQ
Aerovate Therapeutics Insider Sold Shares Worth $908,046, According to a Recent SEC Filing	Mar. 21	MT
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair	Mar. 06	AQ
Aerovate Therapeutics, Inc. Announces Board Changes	Mar. 06	CI
Aerovate Therapeutics : March 2024 Corporate Presentation	Mar. 01	PU
Aerovate Therapeutics Insider Sold Shares Worth $165,628, According to a Recent SEC Filing	Dec. 08	MT
Aerovate Therapeutics : December 2023 Corporate Presentation	Dec. 01	PU
Aerovate Therapeutics Insider Sold Shares Worth $203,237, According to a Recent SEC Filing	Nov. 30	MT
Aerovate Therapeutics Completes Enrollment in Phase 2b Portion of Trial for Treatment of Pulmonary Arterial Hypertension	Nov. 20	MT
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2B Portion and Enrollment of First Patient into Phase 3 in the Impahct Trial Evaluating Av-101 for the Treatment of Pulmonary Arterial Hypertension	Nov. 20	CI
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension	Nov. 20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Aerovate Therapeutics, Inc.

Equities

AVTE

US0080641071

Summary

Filters